ANGPT2抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 80 μg, Lane: Mouse kidney tissue, Primary antibody: P00153(ANGPT2 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P00153(ANGPT2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P00153(ANGPT2 Antibody) at dilution 1/45. (Original magnification: ×200)    

  
  

The angiopoietin-2 (ANGPT2) antibody is a therapeutic or research tool targeting ANGPT2. a key regulator of vascular biology. ANGPT2. part of the angiopoietin family, binds to the Tie2 receptor and modulates endothelial cell signaling. Unlike angiopoietin-1 (ANGPT1), which stabilizes blood vessels by promoting Tie2 activation, ANGPT2 often acts as a context-dependent antagonist. It is highly expressed in pathological conditions involving vascular remodeling, such as tumor angiogenesis, inflammatory diseases, and ischemic retinopathies. ANGPT2 destabilizes vasculature by competing with ANGPT1 for Tie2 binding, increasing vascular permeability and promoting sprouting angiogenesis. This dual role makes it a critical player in diseases like cancer, where it facilitates tumor progression and metastasis, and in inflammatory disorders like diabetic retinopathy or sepsis.

ANGPT2 antibodies are designed to neutralize its activity, blocking interactions with Tie2 or integrins to inhibit pathological angiogenesis or reduce vascular leakage. Preclinical studies show that ANGPT2 inhibition can suppress tumor growth, enhance chemotherapy efficacy, and mitigate inflammatory damage. Some antibodies also target both ANGPT2 and VEGF pathways to overcome compensatory mechanisms. While early clinical trials in cancers and eye diseases have demonstrated safety and preliminary efficacy, challenges remain in optimizing target specificity and managing systemic effects. Research continues to explore its therapeutic potential, biomarker utility, and role in vascular normalization strategies.